



**Cell Source to Present at the FireRock Conference and the Life Sciences Summit in New York City on October 28th and 29th, 2014**

TEL AVIV, Israel, Oct. 8, 2014 /PRNewswire/ -- [Cell Source, Inc.](#) (OTCQB: CLCS) ("Cell Source") an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at two upcoming conferences in New York City during the month of October.

On Tuesday, October 28<sup>th</sup> at 10:30 am Mr. Shimrat will present at the [FireRock Conference](#), New York City's premier annual micro-cap conference. The conference is an exclusive gathering of the "Who's who" of the micro-cap space, with a lineup of industry leaders, standout companies and cutting edge [speakers](#) and panelists. Companies and attendees interested in the conference are invited to view the conference [flier](#), and [register](#) at the conference's [website](#).

On Wednesday, October 29<sup>th</sup>, at 10:45 am, Mr. Shimrat will present at the [Life Sciences Summit](#), an investor and business development conference that highlights innovation. The objective of the event is to connect biotech and academic innovators with capital and strategic partners. The two-day program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It also features informative plenary sessions, business workshops, and Key Opinion Leader sessions.

For further information, please visit [www.cell-source.com](http://www.cell-source.com) or contact Itamar Shimrat, President & CEO (646) 416-7896.

**About Cell Source, Inc.**

Cell Source is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies Cell Source's therapies have demonstrated the ability to directly address a number of severe medical conditions including blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Cell Source's organ regeneration platform holds the potential to repair organs and to grow entire organs inside the patient's body. Growing or regenerating organs and using cell therapy to tolerize the immune system can each revolutionize the treatment of numerous severe diseases that today kill hundreds of thousands of patients annually.

**SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995**

*With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.*

SOURCE Cell Source, Inc.